← Back to Search

PARP Inhibitor

Olaparib for Acute Myeloid Leukemia with IDH Mutation

Phase 2
Waitlist Available
Led By Thomas Prebet
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky >= 60%)
Must not have
Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
Patients receiving concurrent chemotherapy, radiation therapy, or immunotherapy for AML/MDS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how well olaparib works in patients with AML or MDS that has come back or does not respond to treatment, and who have an IDH mutation. Olaparib is a pill that may help stop cancer cells from growing by blocking certain enzymes they need. The study aims to see if olaparib is better than other treatments. Olaparib has shown benefits in various cancers, including breast and ovarian cancers.

Who is the study for?
Adults diagnosed with relapsed or refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) with an IDH mutation, who have tried first-line therapy without success. Participants must be in stable health otherwise, not pregnant, and willing to use contraception. Those with uncontrolled infections, other active cancers needing treatment, or known hypersensitivity to olaparib are excluded.
What is being tested?
The trial is testing the effectiveness of Olaparib for patients whose AML or MDS has returned after treatment or hasn't responded at all. The study aims to determine if Olaparib can block enzymes that cancer cells need to grow and whether it's better than standard chemotherapy.
What are the potential side effects?
Olaparib may cause side effects like nausea, fatigue, blood cell count changes leading to increased infection risk, shortness of breath, headaches and dizziness. Some people might experience more serious issues affecting their lungs or kidneys.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My hepatitis B virus is under control with treatment.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
My MDS is classified as intermediate, high, or very high risk with excess blasts.
Select...
I am HIV-positive, on treatment, and my viral load is undetectable.
Select...
I finished chemotherapy 3 weeks ago and radiotherapy 2 weeks ago.
Select...
My cancer has a specific IDH2 mutation.
Select...
My MDS is classified as intermediate, high, or very high risk with excess blasts.
Select...
I am 18 years old or older.
Select...
My cancer has a specific IDH1 mutation.
Select...
My AML or MDS has not responded to the first treatment or has come back after it.
Select...
I have been diagnosed with MDS or AML according to WHO 2016 guidelines.
Select...
My AML or MDS has not responded to or has returned after initial treatment.
Select...
I had a stem cell transplant over 6 months ago, have minimal GVHD, and stopped immunosuppressants 2 weeks ago.
Select...
I had hepatitis C but am cured, or I'm being treated with no detectable virus.
Select...
I have been diagnosed with MDS or AML according to WHO 2016 guidelines.
Select...
I am 18 years old or older.
Select...
My hepatitis B virus load is undetectable with treatment.
Select...
I had hepatitis C but have been treated and cured.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot take pills by mouth or have stomach issues that affect medication absorption.
Select...
I am currently undergoing chemotherapy, radiation, or immunotherapy for AML/MDS.
Select...
I have never been treated with a PARP inhibitor like olaparib.
Select...
I do not have any other cancers that need treatment which would interfere with this study.
Select...
I do not have any ongoing, untreated infections.
Select...
I am not taking strong or moderate CYP3A inhibitor medications.
Select...
I had major surgery more than 2 weeks ago and have recovered from it.
Select...
My brain or spinal cord disease is causing symptoms and is not under control.
Select...
I have heart issues that are not under control or I was born with a condition that affects my heart's rhythm.
Select...
I have lasting side effects from cancer treatment, but not hair loss.
Select...
I am not taking any strong or moderate drugs that affect liver enzymes.
Select...
I do not have any serious, uncontrolled health conditions or infections.
Select...
I have active leukemia in my brain or need ongoing chemotherapy in my spine.
Select...
I haven't had chemotherapy or radiotherapy for 3 weeks, except for pain relief.
Select...
I have been diagnosed with acute promyelocytic leukemia.
Select...
I have had a double umbilical cord blood transplant before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cumulative overall response rate (ORR)
Secondary study objectives
Incidence of adverse events
ORR
Overall survival (OS)
+1 more
Other study objectives
Change in 2-hydroxyglutarate (2HG) levels
Minimal residual disease (MRD) assessment
Mutant allele frequency

Side effects data

From 2023 Phase 3 trial • 154 Patients • NCT02184195
49%
Nausea
47%
Fatigue
38%
Diarrhoea
29%
Abdominal pain
29%
Anaemia
28%
Constipation
27%
Decreased appetite
27%
Back pain
26%
Vomiting
21%
Arthralgia
19%
Pyrexia
18%
Asthenia
13%
Rash
13%
Nasopharyngitis
11%
Alanine aminotransferase increased
11%
Dyspnoea
10%
Neuropathy peripheral
10%
Cough
10%
Abdominal pain upper
10%
Dyspepsia
10%
Anxiety
10%
Pruritus
9%
Hyperglycaemia
9%
Dizziness
9%
Aspartate aminotransferase increased
9%
Thrombocytopenia
9%
Oedema peripheral
9%
Pain in extremity
9%
Insomnia
9%
Stomatitis
9%
Dry mouth
9%
Headache
9%
Neutropenia
8%
Blood creatinine increased
8%
Weight decreased
7%
Dysgeusia
7%
Blood alkaline phosphatase increased
7%
Neutrophil count decreased
7%
Muscle spasms
7%
Influenza
7%
Influenza like illness
7%
Myalgia
7%
Peripheral sensory neuropathy
7%
Gamma-glutamyltransferase increased
6%
Hypertension
6%
Platelet count decreased
6%
Depression
6%
Lymphopenia
6%
Gastrooesophageal reflux disease
6%
Abdominal distension
5%
Musculoskeletal pain
3%
Flank pain
2%
Cholangitis
2%
Flatulence
2%
Paraesthesia
1%
General physical health deterioration
1%
Bladder papilloma
1%
Pneumonia pneumococcal
1%
Abdominal infection
1%
Bartholinitis
1%
Pneumonia
1%
Cerebrovascular accident
1%
Pneumothorax
1%
Gastric varices haemorrhage
1%
Large intestinal obstruction
1%
Cholecystitis
1%
Anastomotic haemorrhage
1%
Device occlusion
1%
Stent malfunction
1%
Bronchiolitis
1%
Empyema
1%
Syncope
1%
Incisional hernia
1%
Device dislocation
1%
Obstruction gastric
1%
Cardiac failure
1%
Vascular stenosis
1%
Pleural effusion
1%
Incarcerated inguinal hernia
1%
Urinary tract infection
1%
Hypothyroidism
1%
Transient ischaemic attack
1%
Infusion related reaction
1%
Duodenal perforation
1%
Melaena
1%
Bile duct obstruction
1%
Pancreatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Olaparib 300 mg Twice Daily (bd)
Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (olaparib)Experimental Treatment3 Interventions
Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity, or absence of remission after 6 cycles for patients without prior exposure to IDH inhibitors, or for up to 12 cycles. Patients also undergo bone marrow aspiration and collection of blood throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2030
Bone Marrow Aspiration
2011
Completed Phase 2
~1740
Olaparib
2007
Completed Phase 4
~2190

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Acute Myeloid Leukemia (AML) include chemotherapy agents like cytarabine and anthracyclines, which work by damaging the DNA of rapidly dividing cells, leading to cell death. Targeted therapies, such as PARP inhibitors like Olaparib, specifically inhibit the PARP enzyme involved in DNA repair, making cancer cells more susceptible to damage and death. This is particularly important for AML patients with specific genetic mutations, such as IDH mutations, as these targeted treatments can be more effective and less toxic than traditional chemotherapy. Understanding these mechanisms helps in tailoring treatment plans to improve outcomes and reduce side effects for AML patients.
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.Childhood acute myeloid leukaemia.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,957 Previous Clinical Trials
41,112,073 Total Patients Enrolled
Thomas PrebetPrincipal InvestigatorYale University Cancer Center LAO
Rory M ShallisPrincipal InvestigatorYale University Cancer Center LAO
1 Previous Clinical Trials
132 Total Patients Enrolled

Media Library

Olaparib (PARP Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03953898 — Phase 2
Acute Myeloid Leukemia Research Study Groups: Treatment (olaparib)
Acute Myeloid Leukemia Clinical Trial 2023: Olaparib Highlights & Side Effects. Trial Name: NCT03953898 — Phase 2
Olaparib (PARP Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03953898 — Phase 2
~3 spots leftby Dec 2025